Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUTยทNASDAQ

$2.58

-3.7%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$327.86M
EPS-0.4700
P/E Ratio-5.49
Earnings Date08/04/2026

No Dividend Yield Data

NAUT has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

NAUT has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

NAUT has not reported any net dividends paid values in the available annual periods.

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Dividend History

NAUT ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

NAUT Dividend Payment History

NAUT ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
naut

Nautilus Biotechnology, Inc. Payout Ratio Analysis

NAUT ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-59.00M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.